PAX3 and neoplasm: Inhibition of PLK1 with the small molecule BI 2536 causes increased proteasomal degradation of PAX3-FOXO1 and tumor regression in a xenograft mouse model, an effect that could be reproduced in a different study using the PLK1 inhibitor Volasertib [85, 86].